Hims & Hers Health, Inc. (NYSE: HIMS) reported Q4 EPS of ($0.05), $0.01 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $167.2 million versus the consensus estimate of $160.8 million.

GUIDANCE:

Hims & Hers Health, Inc. sees Q1 2023 revenue of $175-180 million, versus the consensus of $163 million.

• Adjusted EBITDA of $3 million to $6 million, reflecting an Adjusted EBITDA margin of 2% to 3%.

Hims & Hers Health, Inc. sees FY2023 revenue of $735-755 million, versus the consensus of $727 million.

• Adjusted EBITDA of $20 million to $30 million, reflecting an Adjusted EBITDA margin of 3% to 4%.

2025 Financial Targets

Hims & Hers has demonstrated a consistent track record of execution driven by the strength of its business model and operational excellence, which is fueling strong top line growth and Adjusted EBITDA profitability. Given its large market opportunity and growing customer demand, the Company is providing financial targets for the full year 2025, which include:

• Revenue of at least $1.2 billion.
• Adjusted EBITDA of at least $100 million.

For earnings history and earnings-related data on Hims & Hers Health, Inc. (HIMS) click here.